DDInter1868 DDInter1376
Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Trifluridine {u} (Compound) resembles {v} (Compound) Telbivudine
Trifluridine {u} (Compound) resembles {v} (Compound) Pentostatin
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Trifluridine {u} (Compound) binds {v} (Gene) SLC22A6
Trifluridine {u} (Compound) upregulates {v} (Gene) CRIP1
Trifluridine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Trifluridine {u} (Compound) downregulates {v} (Gene) UBQLN2
Trifluridine {u} (Compound) causes {v} (Side Effect) Keratitis sicca
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegfilgrastim
Trifluridine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Trifluridine (Compound) resembles Telbivudine (Compound)
Trifluridine (Compound) resembles Pentostatin (Compound)
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Trifluridine (Compound) binds SLC22A6 (Gene)
Trifluridine (Compound) upregulates CRIP1 (Gene)
Trifluridine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Trifluridine (Compound) downregulates UBQLN2 (Gene)
Trifluridine (Compound) causes Keratitis sicca (Side Effect)
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim
Trifluridine may lead to a major life threatening interaction when taken with Clozapine